Clinical Efficacy of the MDS Patients Treated by Allo-HSCT.
10.19746/j.cnki.issn.1009-2137.2021.01.027
- Author:
Qing-Yun WANG
1
;
Yu-Jun DONG
1
;
Qian WANG
1
;
Wei LIU
1
;
Yu-Hua SUN
1
;
Yue YIN
1
;
Ze-Yin LIANG
1
;
Wei-Lin XU
1
;
Yuan LI
2
Author Information
1. Department of Hematology，Peking University First Hospital，Beijing 100034，China.
2. Department of Hematology，Peking University First Hospital，Beijing 100034，China,E-mail: drliyuan@75@163.com.
- Publication Type:Journal Article
- MeSH:
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Myelodysplastic Syndromes;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Experimental Hematology
2021;29(1):172-180
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze clinical effectiveness of myelodysplastic syndrome (MDS) patients treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT), and to investigate new therapy strategy for the treatment of relapse after allo-HSCT.
METHODS:72 MDS patients treated by HSCT in our hospital from April 2013 to November 2019 were enrolled and analyzed retrospectively. The effect of allo-HSCT was summarized. The risk factors affecting the survival and relapse of the patients were investigated.
RESULTS:Among 72 patients, the median follow up was 37(12-111) months. 57 patients survived（79.2%），while 15 patients died（20.8%）. The 5-year overall survival (OS) rate and 5-year disease-free survival (DFS) rate were 76.6% and 62.3%, respectively. IPSS-R, TP53 mutation and chronic graft versus-host-disease (cGVHD) were the risk factors affecting the OS of the MDS patients after treated by allo-HSCT. IPSS-R, TP53 mutation and Ⅲ-Ⅳ° acute graft versus-host-disease (aGVHD) were the risk factors affecting the DFS of the MDS patients after treated by allo-HSCT. After transplanted, 19 patients (26.4%) emerged aGVHD, and 5 patients (6.9%) emerged Ⅲ-Ⅳ° aGVHD, 25 patients (34.7%) emerged cGVHD, while 4 patients (5.6%) emerged extensive cGVHD. 17 patients (23.3%) relapsed, and the 5-year cumulative incidence of relapse (CIR) rate was 27.5%. IPSS-R, TP53 mutation and cGVHD were the risk factors affecting the relapse of the patients. The median survival time after relapse was 9 months. There were 7 out of 17 relapsed patients survived without disease, while 10 patients died. The OS rate of patients treated with maintained hypomethylation agents(HMA) combined with G-CSF mobilized donor lymphocyte infusion (DLI) was significantly higher than the patients without HMA (80.0% vs 10.0%, P=0.002).
CONCLUSION:Allo-HSCT is an effective therapy for intermediate and high risk MDS patients. But relapse after HSCT is still a major problem that affecting the survival of the patients. Maintenance treatment of HMA combined with DLI may improve the long-time survival of MDS patients with relapsed after treated by allo-HSCT.
